VistaGen Therapeutics, a
biotechnology company applying pluripotent stem cell technology for drug rescue
and regenerative medicine, reports that it is now a member of the Cardiac
Safety Technical Committee, Cardiac Stem Cell Working Group, and Proarrhythmia
Working Group of the Health and Environmental Sciences Institute (HESI).
Using mature cardiomyocytes
(heart cells) differentiated from human pluripotent stem cells, VistaGen
developed its CardioSafe 3D™ bioassay system to predict the in vivo cardiac effects,
both toxic and non-toxic, of small molecule drug candidates with greater speed
and precision than the traditional, surrogate safety models most often used in
drug development. The company’s pluripotent stem cell-derived heart cells and
CardioSafe 3D are vital components of its Human Clinical Trials in a Test Tube™
platform and drug rescue programs.
Ralph Snodgrass, Ph.D.,
VistaGen’s president and chief scientific officer commented, “We look forward
to collaborating with leading pharmaceutical, biotechnology, academic, and
regulatory members of the HESI’s Cardiac Safety Technical Committee, and
related working groups, to help advance, among other goals, the FDA’s CIPA
initiative, which is focused on developing innovative preclinical systems for
cardiac safety assessment during drug development.”
HESI, a global branch of the
International Life Sciences Institute (ILSI), boasts a membership roll that
includes most of the world’s largest biotechnology and pharmaceutical companies
for which it provides an international forum to advance the understanding of
scientific issues related to human health, toxicology, risk assessment, and the
environment. ILSI is a nonprofit, worldwide organization whose mission is to
provide science that improves human health and well-being and safeguards the
environment.
Operating from its
headquarters in San Francisco, California, VistaGen contends that better cells
lead to better medicine and that the key to making better cells is controlling
with precision the differentiation of human pluripotent stem cells, which are
the base cells of the human body.
For more information on the
company visit www.VistaGen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
